Rosuvamibe + Monorova
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease, Type 2 Diabetes
Trial Timeline
Mar 27, 2018 → Dec 1, 2021
NCT ID
NCT03403556About Rosuvamibe + Monorova
Rosuvamibe + Monorova is a approved stage product being developed by Yuhan for Atherosclerotic Cardiovascular Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT03403556. Target conditions include Atherosclerotic Cardiovascular Disease, Type 2 Diabetes.
What happened to similar drugs?
6 of 20 similar drugs in Atherosclerotic Cardiovascular Disease were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03597412 | Approved | Completed |
| NCT03403556 | Approved | UNKNOWN |
| NCT03494270 | Approved | Completed |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease